Controlled-release oxycodone-induced seizures

被引:4
|
作者
Klein, M [1 ]
Rudich, Z
Gurevich, B
Lifshitz, M
Brill, S
Lottan, M
Weksler, N
机构
[1] Ben Gurion Univ Negev, Div Anesthesiol & Crit Care Med, Soroka Med Ctr, Fac Hlth Sci, IL-84101 Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Dept Pediat, Soroka Med Ctr, Fac Hlth Sci, IL-84101 Beer Sheva, Israel
[3] Ben Gurion Univ Negev, Toxicol Unit, Soroka Med Ctr, Fac Hlth Sci, IL-84101 Beer Sheva, Israel
[4] Haim Sheba Med Ctr, Dept Anesthesiol & Intens Care, Pain Clin, Tel Hashomer, Israel
[5] Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel
[6] Tel Aviv Univ, Sackler Sch Med, Dept Anesthesiol, Obstet Anesthesia Unit, IL-69978 Tel Aviv, Israel
关键词
oxycodone; seizure; carbamazepine;
D O I
10.1016/j.clinthera.2005.11.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The use of the opioid oxycodone hydrochloride in the management of chronic pain is gaining popularity principally because of its tolerability. However, opioid-related seizure in patients with epilepsy or other conditions that may decrease seizure threshold has been described in the literature; in particular, oxycodone has been associated with seizure in a patient with acute renal failure. Objective: The aim of this article was to report a patient with a history of seizures but normal renal and hepatic function who developed seizure on 2 occasions after oxycodone ingestion. Methods: A 54-year-old male patient presented with a history of tonic-clonic seizures that developed immediately after intracranial surgery. Long-term treatment with carbamazepine 400 mg QD was started, and the patient was free of convulsions for similar to 7 years. The patient presented to us with severe headache that was nonresponsive to an NSAID and the opiate agonist tramadol. Treatment with controlled-release (CR) oxycodone and tramadol drops (50 mg QID if necessary) was started, and tonic-clonic seizures developed 3 days later. Results: Based on laboratory analysis, the patient had normal renal and hepatic function. On discontinuation of oxycodone treatment, the seizures resolved. However, due to effective pain relief with oxycodone, the patient decided to continue treatment, and seizures recurred. Carbamazepine was then administered 4 hours before oxycodone dosing, which allowed continuation of treatment without seizure. Conclusions: A patient with a history of seizures controlled with long-term carbamazepine therapy developed seizures when he started treatment with oxycodone CR at recommended doses. Oxycodone CR should be used with extreme caution in patients with epilepsy or other conditions that may decrease seizure threshold.
引用
收藏
页码:1815 / 1818
页数:4
相关论文
共 50 条
  • [1] Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model
    Curtis, GB
    Johnson, GH
    Clark, P
    Taylor, R
    Brown, J
    O'Callaghan, R
    Shi, M
    Lacouture, PG
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (06) : 425 - 429
  • [2] A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone
    Benziger, DP
    Miotto, J
    Grandy, RP
    Thomas, GB
    Swanton, RE
    Fitzmartin, RD
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (02) : 75 - 82
  • [3] Advancement of opioid analgesia with controlled-release oxycodone
    Levy, MH
    EUROPEAN JOURNAL OF PAIN-LONDON, 2001, 5 : 113 - 116
  • [4] Controlled-release oxycodone for the management of pediatric postoperative pain
    Czarnecki, ML
    Jandrisevits, MD
    Theiler, SC
    Huth, MM
    Weisman, SJ
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 27 (04) : 379 - 386
  • [5] Controlled-release oxycodone and morphine in cancer related pain
    Heiskanen, T
    Kalso, E
    PAIN, 1997, 73 (01) : 37 - 45
  • [6] Characterization and validation of a pharmacokinetic model for controlled-release oxycodone
    Mandema, JW
    Kaiko, RF
    Oshlack, B
    Reder, RF
    Stanski, DR
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) : 747 - 756
  • [7] Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
    Lee, Kyung-Hee
    Kim, Tae Won
    Kang, Jung-Hun
    Kim, Jin-Soo
    Ahn, Jin-Seok
    Kim, Sun-Young
    Yun, Hwan-Jung
    Eum, Young-Jun
    Koh, Sung Ae
    Kim, Min Kyoung
    Hong, Yong Sang
    Kim, Jeong Eun
    Lee, Gyeong-Won
    CHINESE JOURNAL OF CANCER, 2017, 36
  • [8] Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain:a randomized controlled trial
    KyungHee Lee
    Tae Won Kim
    JungHun Kang
    JinSoo Kim
    JinSeok Ahn
    SunYoung Kim
    HwanJung Yun
    YoungJun Eum
    Sung Ae Koh
    Min Kyoung Kim
    Yong Sang Hong
    Jeong Eun Kim
    GyeongWon Lee
    ChineseJournalofCancer, 2017, 36 (11) : 609 - 617
  • [9] Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy
    Davis, MP
    Varga, J
    Dickerson, D
    Walsh, D
    LeGrand, SB
    Lagman, R
    SUPPORTIVE CARE IN CANCER, 2003, 11 (02) : 84 - 92
  • [10] Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain
    Hagen, NA
    Babul, N
    CANCER, 1997, 79 (07) : 1428 - 1437